Loading
A phase 3 trial of Acalabrutinib and Ibrutinib in chronic lymphocytic leukaemia, run by Acerta Pharma BV, active and no longer recruiting.
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL) is a phase 3 interventional study registered as NCT02477696 by Acerta Pharma BV, with 533 participants enrolled, started 2015-07-28 and due to reach its primary completion in 2020-09-15. Interventions recorded: Acalabrutinib and Ibrutinib. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
533 enrolled.
95% CI 33.0 to 38.6; Figures from the ClinicalTrials.gov results section (first posted 2022-01-28), not from a publication · 95% CI 33.0 to 41.6
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free Survival (PFS) Based on Independent Review Committee (IRC) Assessmentprimary | Acalabrutinib | 268 | 38.4 months | 1 (0.79 to 1.27) | - | link |
| Ibrutinib | 265 | 38.4 months |
Shares Acalabrutinib, Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia, AstraZeneca and the tag pipeline.
Shares Acalabrutinib, Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia, AstraZeneca and the tag pipeline.
Shares Acalabrutinib, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Ibrutinib, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Acalabrutinib, Chronic lymphocytic leukaemia, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Acalabrutinib, Chronic lymphocytic leukaemia, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.